AMOYTOP(SH:688278) Ge Long Hui A P P·2025-08-20 10:24Core Viewpoint - The report indicates significant growth in revenue and net profit for the company, driven by an increasing number of patients receiving its core product, Pegasys, due to the rising awareness of hepatitis B clinical cure concepts [1] Financial Performance - The company achieved a revenue of 1.511 billion yuan, representing a year-on-year increase of 26.96% [1] - The net profit attributable to shareholders reached 428 million yuan, marking a year-on-year growth of 40.60% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 431 million yuan, reflecting a year-on-year increase of 30.68% [1] - Basic earnings per share stood at 1.05 yuan [1] Growth Drivers - The primary reason for the revenue growth is the increasing number of patients receiving treatment with the company's core product, Pegasys, as the concept of clinical cure for hepatitis B becomes more widely accepted and supported by scientific evidence [1]